Patents Assigned to Merck
  • Human neuronal nicotinic acetylcholine receptor &agr;6 and &bgr;3 nucleic acid
    Patent number: 6485967
    Abstract: DNA encoding human neuronal nicotinic acetylcholine receptor alpha and beta subunits, mammalian and amphibian cells containing said DNA, methods for producing alpha and beta subunits and recombinant (i.e., isolated or substantially pure) alpha subunits (specifically &agr;6) and beta subunits (specifically &bgr;3) are provided. In addition, combinations of a plurality of subunits (i.e., one or more of as &agr;1, &agr;2, &agr;3, &agr;4, &agr;5, &agr;6 and/or &agr;7 subunits in combination with one or more of &bgr;3 subunits are provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 26, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Kathryn J. Elliott, Michael M. Harpold
  • Process for formulation of antibiotic compounds
    Patent number: 6486150
    Abstract: The present invention involves a process for preparing a stable final formulation product of a compound of formula I, or its pharmaceutically acceptable salt, hydrate or solvate by incorporating a suitable carbon dioxide source to an unstable monosodium adduct of carbapenem antibiotic compound.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: November 26, 2002
    Assignee: Merck & Co., Inc.
    Inventors: William A. Hunke, Kathleen J. Illig, Anand Kanike, Scott D. Reynolds, Stelios C. Tsinontides, Anthony S. Al-Dehneh, Hiren S. Patel
  • Treatment or prevention of prostate cancer with a COX-2 selective inhibiting drug
    Patent number: 6486204
    Abstract: A COX-2 selective inhibiting drug is disclosed as useful in treating or preventing prostate cancer. The compound is used alone or in combination with other drugs.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: November 26, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Joanne Waldstreicher, Briggs W. Morrison
  • Bone cement paste containing an antibiotic
    Patent number: 6485754
    Abstract: The invention relates to an injectable curable bone cement paste based on bioresorbable hydroxyapatite-like compounds comprising calcium phosphate, which contains a cationic antibiotic in the form of a salt, preferably of its sulfate, the curable biodegradable bone cement releasing the antibiotic in biologically active concentrations with depot-like action over a long period of time. The bone cements according to the invention are suitable for the treatment of infectious inflammations of the bone and of the bone marrow, in particular as a result of bone defects and bone fractures.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: November 26, 2002
    Assignee: Merck Patent GmbH
    Inventors: Robert Wenz, Berthold Nies
  • Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
    Patent number: 6486142
    Abstract: The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and conditions related to diabetes.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: November 26, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yves Leblanc, Claude Dufresne, Jacques Yves Gauthier, Cheuk Kun Lau, Chun Sing Li, Patrick Roy, Michel Therien, John Scheigetz, Zhaoyin Wang
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Publication number: 20020173661
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Application
    Filed: March 20, 2002
    Publication date: November 21, 2002
    Applicant: Merck Frosst Canada & Co.
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Substituted cyclic amidine derivatives as inhibitors of cell adhesion
    Patent number: 6482840
    Abstract: Compounds of Formula I are antagonists of VLA-4 and/or &agr;4&bgr;7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: November 19, 2002
    Assignee: Merck & Co., Inc.
    Inventors: William K. Hagmann, George A. Doherty, Shrenik Shah
  • Process for preparing acetonides
    Patent number: 6482952
    Abstract: Acetonides are obtained in a one-step reaction of a carboxylic acid halide, a 1,2-aminoalcohol, and 2-alkoxypropene or 2,2-dialkoxypropane in an ether solvent and in the presence of an inorganic base. Acetonides are also obtained in a two-step reaction scheme in which an acid halide and 1,2-aminoalcohol are reacted in an ether solvent in the presence of LiOH to form a hydroxyamide, which is then reacted with 2-alkoxypropene or 2,2-dialkoxypropane in the presence of acid to form the acetonide. The acetonides resulting from the one-step and two-step protocols can be further reacted with an allylating agent such as an allyl halide in the presence of a strong base to provide the corresponding allyl acetonide. The acetonides and allyl acetonides can serve as intermediates in the production of certain HIV protease inhibitors which are useful for treating HIV infection and AIDS.
    Type: Grant
    Filed: June 18, 2001
    Date of Patent: November 19, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Steven J. Cianciosi, Gregory L. Tewalt, Eric T. Pisk, Ilia A. Zavialov, Glenn A. Hulvey
  • Use of alendronate for the prevention of osteoporosis
    Publication number: 20020169148
    Abstract: Alendronate, an aminobisphosphonate, can prevent osteoporosis in early post menopausal women.
    Type: Application
    Filed: April 2, 2002
    Publication date: November 14, 2002
    Applicant: Merck & Co., Inc.
    Inventor: Ashley J. Yates
  • Arylalkanoyl pyridazines
    Patent number: 6479494
    Abstract: Arylalkanoylpyridazine derivatives of the formula I and the physiologically acceptable salts thereof in which R1, R2, R3, R4, Q and B have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases and AIDS.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: November 12, 2002
    Assignee: Merck Patent Gesellschaft Mit Beschraenkter Haftung
    Inventors: Jonas Rochus, Norbert Beier, Franz-Werner Kluxen, Michael Wolf
  • Phenylindole derivatives as 5-ht2a receptor ligands
    Patent number: 6479480
    Abstract: Compounds according to Formula (I) or a salt thereof are selective antagonists of the human 5-HT2A receptor useful for treatment of adverse conditions of the central nervous system:
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: November 12, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Christopher Richard Moyes, Michael Rowley
  • Zwitterionic tachykinin receptor antagonists
    Patent number: 6479518
    Abstract: The present invention is directed to certain novel compounds represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein R3, R5, R6, R7, R8, R11, R12, R13, Q, W, X, Y and Z are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of psychiatric disorders including depression and anxiety.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: November 12, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Paul E. Finke, Laura C. Meurer, Sander G. Mills, Malcolm MacCoss, Hongbo Qi
  • Triazolo-pyridine derivatives as ligands for GABA receptors
    Patent number: 6479506
    Abstract: Substituted or 6,7-ring fused 1,2,3-triazolo[4,5-b]pyridine derivatives are selective ligands for GABAA receptors useful in the treatment of disorders of the central nervous system.
    Type: Grant
    Filed: November 7, 2000
    Date of Patent: November 12, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Howard Barff Broughton, Jose Luis Castro Pineiro, Ian James Collins, Leslie Joseph Street
  • Diastereoselective preparation of Michael adducts
    Patent number: 6479672
    Abstract: Michael addition conducted in the presence of a zinc-amine complex and additional amounts of the amine component results in product with high diastereomeric excess.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: November 12, 2002
    Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd,
    Inventors: Ioannis Houpis, Ralph P. Volante, Fengrui Lang, Ilias Dorziotis, David Tschaen, Shinji Kato, Toshiaki Mase
  • Method for the immunological determination of an analyte
    Patent number: 6479302
    Abstract: The invention concerns a method for the immunological determination of an analyte in a sample using magnetic particles coated with the analyte to be determined or analyte-specific bonding partners and directly detectable non-magnetic particles coated with analyte-specific bonding partners or the analyte to be determined or using a non-magnetic substance which is indirectly detectable, and incubation of the reaction mixture. The method is characterized in that the magnetic particles are subsequently separated from the reaction mixture using a magnetic test strip and the analyte concentration is determined directly.
    Type: Grant
    Filed: November 17, 1999
    Date of Patent: November 12, 2002
    Assignee: Merck Patent Gesellschaft MIT
    Inventor: Bernd Dremel
  • Crystalline forms of antibiotic side chain intermediates
    Patent number: 6479667
    Abstract: Crystalline 2S-cis-3-[[(4-mercapto-2-pyrrolidinyl)carbonyl]-amino]benzoic acid and salts and solvates thereof are disclosed. A crystalline type is described.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: November 12, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Karel J. M. Brands, Karen M. Conrad, John M. Williams
  • Tyrosine kinase inhibitors
    Patent number: 6479512
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 17, 2000
    Date of Patent: November 12, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Scott R. Hambaugh, Randall W. Hungate
  • Removal of contaminants from biological products
    Patent number: 6478967
    Abstract: The invention relates to methods for separating biological contaminants (viruses, nucleic acids and/or endotoxins) from biological products, or for reducing the content of such biological contaminants in said biological products. The sample (biological product) to be purified is treated with an anion exchanger membrane. Said anion exchanger membrane is obtained by reacting a polyamide with an aminoreactive compound which is capable of polymerisation. This is followed by polymerisation with monomers which contain cationic groups or into which cationic groups can be introduced in a reaction analogous to polymerisation.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: November 12, 2002
    Assignee: Merck Patent Gesellschaft MIT
    Inventor: Egbert Müller
  • Method for symmetrically and asymmetrically disubstituting carboxylic acid amides with organotitanates and grignard reagents
    Patent number: 6479661
    Abstract: The invention relates to a method for disubstituting carboxylic acid amides on a geminal carbonyl-C-atom using a Grignard reagent in the presence of an organotitanate.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: November 12, 2002
    Assignee: Merck Patent Gesellschaft
    Inventors: Herwig Buchholz, Urs Welz-Biermann, Armin Meijere, Vladimir Chaplinski
  • Azabicyclic spiroether derivatives and their use as therapeutic agents
    Patent number: 6479486
    Abstract: The present invention relates compounds of the formula (I): wherein Z is —CR9R10CH2— or —CH2CR9R10—; and R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or postherpetic neuralgia.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: November 12, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Ian Thomas Huscroft, Janusz Jozef Kulagowski, Piotr Antoni Raubo